OBJECTIVE: To determine neurocognitive function in HIV-infected subjects with low weight and weight loss. DESIGN: Cross-sectional cohort. METHODS: Baseline data from male and female participants in longitudinal treatment studies of AIDS wasting were analyzed. Fifty-seven HIV-infected women (age: 38 +/- 5 years, education level: 12.3 +/- 2.3 years) and 24 HIV-infected men (age: 37 +/- 5 years, education level: 13.5 +/- 2.9 years) with weight <90% IBW or loss of >10% of preillness weight maximum underwent standardized neurocognitive testing to measure intellectual functioning, attention, memory, and fine motor dexterity. The z scores were determined using age- and gender-specific normative data. RESULTS: Among women, IQ (87 +/- 13, z score: -0.8 +/- 0.8 SD) and executive functioning scores (-0.7 +/- 1.2 SD) were below average but within normal limits. In contrast, performance (z scores) on measures of verbal learning (-2.5 +/- 1.5 SD), visuospatial abilities (-2.5 +/- 2.0 SD), and motor coordination (-2.3 +/- 3.3 SD) fell significantly below normal limits. Among men, IQ score was 96 +/- 13 SD (z score: -0.3 +/- 0.8 SD). Performance was below average on measures of verbal learning (-1.0 +/- 1.7 SD) and visual construction (-1.6 +/- 1.7 SD) but within normal limits on executive functioning (-0.1 +/- 1.0 SD). CONCLUSIONS: HIV-infected women at low weight demonstrate significantly reduced verbal learning, memory, and motor function, whereas HIV-infected men at low weight demonstrate more moderate impairment in verbal learning and other measures of neurocognitive function.
OBJECTIVE: To determine neurocognitive function in HIV-infected subjects with low weight and weight loss. DESIGN: Cross-sectional cohort. METHODS: Baseline data from male and female participants in longitudinal treatment studies of AIDS wasting were analyzed. Fifty-seven HIV-infectedwomen (age: 38 +/- 5 years, education level: 12.3 +/- 2.3 years) and 24 HIV-infectedmen (age: 37 +/- 5 years, education level: 13.5 +/- 2.9 years) with weight <90% IBW or loss of >10% of preillness weight maximum underwent standardized neurocognitive testing to measure intellectual functioning, attention, memory, and fine motor dexterity. The z scores were determined using age- and gender-specific normative data. RESULTS: Among women, IQ (87 +/- 13, z score: -0.8 +/- 0.8 SD) and executive functioning scores (-0.7 +/- 1.2 SD) were below average but within normal limits. In contrast, performance (z scores) on measures of verbal learning (-2.5 +/- 1.5 SD), visuospatial abilities (-2.5 +/- 2.0 SD), and motor coordination (-2.3 +/- 3.3 SD) fell significantly below normal limits. Among men, IQ score was 96 +/- 13 SD (z score: -0.3 +/- 0.8 SD). Performance was below average on measures of verbal learning (-1.0 +/- 1.7 SD) and visual construction (-1.6 +/- 1.7 SD) but within normal limits on executive functioning (-0.1 +/- 1.0 SD). CONCLUSIONS:HIV-infectedwomen at low weight demonstrate significantly reduced verbal learning, memory, and motor function, whereas HIV-infectedmen at low weight demonstrate more moderate impairment in verbal learning and other measures of neurocognitive function.
Authors: Allison J Applebaum; Laura C Reilly; Jeffrey S Gonzalez; Mark A Richardson; Catherine L Leveroni; Steven A Safren Journal: AIDS Patient Care STDS Date: 2009-06 Impact factor: 5.078
Authors: Eva M Müller-Oehring; Rosemary Fama; Taylor F Levine; Cheshire Hardcastle; Ryan Goodcase; Talora Martin; Varsha Prabhakar; Helen M Brontë-Stewart; Kathleen L Poston; Edith V Sullivan; Tilman Schulte Journal: J Neuropsychol Date: 2020-10-08 Impact factor: 2.864
Authors: Taofiki A Sunmonu; Johann Sellner; Olubunmi A Ogunrin; Frank A Imarhiagbe; Morenikeji A Komolafe; Olusegun T Afolabi; Olayinka S Ilesanmi; Fatai Olanrewaju; Benedicta Y Oladimeji Journal: Biomed Res Int Date: 2015-07-29 Impact factor: 3.411
Authors: Taofiki A Sunmonu; Olubunmi A Ogunrin; Frank A Imarhiagbe; Lukman F Owolabi; Morenikeji A Komolafe; Olayinka S Llesanmi Journal: eNeurologicalSci Date: 2016-02-24
Authors: J S Huang; S Letendre; J Marquie-Beck; M Cherner; J A McCutchan; I Grant; R Ellis Journal: J Neuroimmune Pharmacol Date: 2007-10-10 Impact factor: 7.285